A Case of Rapidly Progressing Hepatocellular Carcinoma after Administration of JAK Inhibitors to Treat Rheumatoid Arthritis

We report a case of rapidly progressing hepatocellular carcinoma after administration of Janus kinase (JAK) inhibitors to treat rheumatoid arthritis. A 76-year-old man was referred to our Department for pain in multiple joints and was diagnosed with rheumatoid arthritis. Blood tests revealed elevate...

Full description

Saved in:
Bibliographic Details
Main Authors: Rioko Migita, Yasutaka Kimoto, Junki Hiura, Yuta Okumura, Takahiko Horiuchi
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Case Reports in Rheumatology
Online Access:http://dx.doi.org/10.1155/2022/6852189
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report a case of rapidly progressing hepatocellular carcinoma after administration of Janus kinase (JAK) inhibitors to treat rheumatoid arthritis. A 76-year-old man was referred to our Department for pain in multiple joints and was diagnosed with rheumatoid arthritis. Blood tests revealed elevated hepatobiliary enzymes, but various tests revealed no signs suggestive of malignancy. He took baricitinib for 2 months followed by tofacitinib for 4 months. After that, he was diagnosed with hepatocellular carcinoma based on imaging findings and elevated tumor markers. This case showed the possibility of a causal relationship between JAK inhibitors and malignancy.
ISSN:2090-6897